Delivery strategies to overcome tumor immunotherapy resistance

Lanhong Su, Guiyuan Chen, Zhaoji Liu, Yuanzeng Min, Andrew Z. Wang

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Immunotherapy is a promising treatment for cancer nowadays, which induces a long-lasting response in contrast to chemotherapy and radiotherapy. The immunotherapies, mainly including immune checkpoint blockade therapy, adoptive cell therapy, and therapeutic cancer vaccines, have yielded remarkable clinical outcomes in cancer patients. However, most of the patients did not benefit from immunotherapy due to primary resistance and only a small part of initial responders developed acquired resistance that relapsed after a period of treatment. Improving the efficacy of immunotherapy is necessary to understand the mechanisms of immunotherapy resistance, namely primary resistance and acquire resistance, and then develop combination therapies through various delivery strategies to overcome immunotherapy resistance. In this chapter, we review different types of cancer immunotherapy, elaborate the predominant mechanisms of immunotherapy resistance and describe several delivery strategies at the proof-of-concept or clinical trial phase that can overcome tumor immunotherapy resistance.

Original languageEnglish (US)
Title of host publicationSystemic Drug Delivery Strategies
Subtitle of host publicationVolume 2 of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy
PublisherElsevier
Pages529-547
Number of pages19
ISBN (Electronic)9780323857819
DOIs
StatePublished - Jan 1 2021
Externally publishedYes

Keywords

  • Acquired resistance
  • Adoptive cell therapy
  • Combination therapy
  • Delivery strategy
  • Immune checkpoint blockade therapy
  • Immunotherapy
  • Primary resistance
  • Therapeutic cancer vaccine

ASJC Scopus subject areas

  • Economics, Econometrics and Finance(all)
  • Business, Management and Accounting(all)

Fingerprint

Dive into the research topics of 'Delivery strategies to overcome tumor immunotherapy resistance'. Together they form a unique fingerprint.

Cite this